|
|
|||
|
|
||
|
|||
|
Matthew Cu and Mary Blair, Beckman Coulter Inc. Figure 1. Biomek 3000 Laboratory Automation Workstation with integrated Peltier devices. Picture shows an enlarged view of the devices: Peltier Thermoshaker and Peltier Static. Isolating templates suitable for sequencing can be challenging particularly with the wide range of vectors used in sequencing today. In the case of manual plasmid preparations, purification is labor-intensive and time- consuming. An automated method was developed for ease-of-use on the Biomek 3000 Laboratory Automation Workstation to isolate templates suitable for capillary sequencing. The automated plasmid-purification protocol employs the Agencourt CosMCPrep kit for high-throughput preparation of high-copy or low-copy plasmids, BAC or YAC DNA from bacterial cultures. The Agencourt CosMCPrep method incorporates a simplified, graphical user interface to allow for sample plate customization. Default settings; such as sample type, number of samples, plate dry time and elution volume; provide a general starting point for the user. The purification process uses alkaline lysis to break open cell membranes followed by Agencourt SPRI® (Solid Phase Reversible Immobilization) technology, which differentially binds plasmid DNA to paramagnetic particles. While the DNA remains affixed to the beads, contaminants can be rinsed away during a washing procedure. After the processing plate is dried, an elution buffer is added to separate the plasmid DNA from the beads. Purified samples can be used in various downstream applications, such as PCR* amplification and fluorescent DNA sequencing. The information presented here includes the full description of the automated method and subsequent results. Click here for this poster (PDF) Request More Info on Beckman Coulter Automated Solutions >>
Additional Information
Application System Requirements Hardware Options
Software Options
Consumables and Reagents
* All trademarks are the property of their respective owners. Where applicable, the PCR process is covered by patents owned by Roche Molecular Systems, Inc., and F. Hoffmann-LaRoche, Ltd. § May use equivalent substitution For Research Use Only; not for use in diagnostic procedures. For comments or questions about T3 Update, please contact the T3 Editor. Email this page to a colleague
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
